Applied Genetic Technologies (NASDAQ:AGTC) perks up 6% after hours ahead of tomorrow’s announcement of preliminary six-month data from the expansion group in a Phase 1/2 clinical trial evaluating its recombinant adeno-associated virus vector rAAV2tYF-GRK1-RPGR in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
The conference call will start at 8:00 am ET.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.